Natalizumab
- Biologic
- Tysabri
Therapy management checklist
Screening, baseline and ongoing monitoring with the label's stated frequency, hold and discontinue criteria, and counseling points, each quoted from the FDA label.
Loading the therapy management checklist…
Storage and cold chain
Natalizumab: storage and handling
- Refrigerate
- Yes, as the label states
Label statement
TYSABRI single-dose vials must be refrigerated between 2°C to 8°C (36°F to 46°F).
- Freezing
- Not addressed
- Room temperature
- No allowance stated
- Back into the refrigerator
- Not addressed
- Light
- Protect from light
Label statement
Protect from light.
- Shaking
- Do not shake
Label statement
DO NOT SHAKE OR FREEZE.
All storage statements on the label (5)
- TYSABRI single-dose vials must be refrigerated between 2°C to 8°C (36°F to 46°F).
- Do not use beyond the expiration date stamped on the carton and vial label.
- DO NOT SHAKE OR FREEZE.
- Protect from light.
- Store diluted TYSABRI solution refrigerated at 2°C to 8°C (36°F to 46°F) [ see Dosage and Administration ( 2.3 ) ]
FDA label version 47, effective March 21, 2025. DailyMed
Dosing and titration calendar
Built only from the schedules the label states (loading, titration, day schedules, cycles and weight bands). Steps the label states in words the calendar cannot place are shown, not guessed.
Loading dosing schedules…
Biosimilars
Tysabri: 1 licensed biosimilar product, 0 interchangeable (FDA Purple Book). Compare presentations and dates
Medicare Part D coverage
No Part D formulary in the CMS files (2026Q3) lists this drug. It may be covered under Part B or not covered.
Patient assistance
No manufacturer program page is listed for this drug yet.
Independent foundations and the full directory (checked 2026-11-06). Eligibility and amounts are set by each program; open its page for them.
For licensed clinicians. Use with clinical judgment. Statements are quoted from the FDA label; confirm against the label for the product you are using.